Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer

Author:

Leo Javier12,Dondossola Eleonora3ORCID,Basham Kaitlin J4ORCID,Wilson Nathaniel R5ORCID,Alhalabi Omar3ORCID,Gao Jianjun3ORCID,Kurnit Katherine C6ORCID,White Michael G7,McQuade Jennifer L8ORCID,Westin Shannon N9ORCID,Wellberg Elizabeth A10ORCID,Frigo Daniel E131112ORCID

Affiliation:

1. Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center , Houston, TX 77054 , USA

2. The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences , Houston, TX 77030 , USA

3. Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

4. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT 84112 , USA

5. Department of Internal Medicine, University of Texas Health Science Center at Houston , Houston, TX 77030 , USA

6. Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The University of Chicago , Chicago, IL 60637 , USA

7. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

8. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

9. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

10. Department of Pathology, Harold Hamm Diabetes Center, and Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104 , USA

11. Center for Nuclear Receptors and Cell Signaling, University of Houston , Houston, TX 77204 , USA

12. Department of Biology and Biochemistry, University of Houston , Houston, TX 77204 , USA

Abstract

AbstractThe androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens include some form of AR modulation. In this regard, AR remains the central driver of prostate cancer cell biology. Emerging preclinical and clinical data implicate key roles for AR in additional cancer types, thereby expanding the importance of this drug target beyond prostate cancer. In this mini-review, new roles for AR in other cancer types are discussed as well as their potential for treatment with AR-targeted agents. Our understanding of these additional functions for AR in oncology expand this receptor's potential as a therapeutic target and will help guide the development of new treatment approaches.

Funder

National Institutes of Health

Publisher

The Endocrine Society

Subject

Endocrinology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3